{"id":"W4416391857","doi":"10.1016/j.annonc.2025.09.087","title":"LBA73 Final overall survival (OS) and safety analysis of the phase III ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System","funders":"Foundation Medicine; Genentech; PharmaMar; AstraZeneca Korea; Ipsen; BeiGene; Mirati Therapeutics; AstraZeneca; Novocure; LG Chem; Regeneron Pharmaceuticals; Yuhan; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Pfizer; Incyte; F. Hoffmann-La Roche; Chugai Pharmaceutical; Celltrion; Roche; Relay Therapeutics; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Alectinib; Crizotinib; Overall survival; Lung cancer; Phases of clinical research; Survival analysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00175223,0.0008148141,0.001506935,0.0003576306,0.0002769761,0.001355917,0.0005806629,0.0006271133,0.003116223],"category_scores_gemma":[0.001202531,0.000305376,0.002772189,0.0004575767,0.0006609865,0.0007340197,0.0003372618,0.002220019,0.0005730857],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001219051,"about_ca_system_score_gemma":0.001333191,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001282714,"about_ca_topic_score_gemma":0.0042912,"domain_scores_codex":[0.9993326,0.000312698,0.00003286773,0.0000976248,0.0000782815,0.000145851],"domain_scores_gemma":[0.999317,0.000174753,0.0001998663,0.00006223971,0.00004615577,0.0001999277],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.88705,0.00530941,0.02054868,0.0006129263,0.006098477,0.000127817,0.00009588542,0.003851628,0.01179095,0.0004280411,0.003132725,0.06095338],"study_design_scores_gemma":[0.494996,0.352927,0.1167159,0.0001473969,0.01209233,0.0006147778,0.0002375951,0.006889938,0.006067912,0.001137358,0.00806297,0.0001107649],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939299,0.002045381,0.0002043451,0.0002719986,0.00007295,0.0001830604,0.001110682,0.00003684382,0.002144808],"genre_scores_gemma":[0.9956654,0.0006749119,0.0002430647,0.0002642285,0.00009057813,0.0001626843,0.001741284,0.00001769927,0.001140304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003116223,"threshold_uncertainty_score":0.01042479,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01963328254977119,"score_gpt":0.3854270002300882,"score_spread":0.365793717680317,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}